According to OPKO Health 's latest financial reports the company's current revenue (TTM) is $0.79 B. In 2022 the company made a revenue of $1.00 B a decrease over the years 2021 revenue that were of $1.77 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.86 B | -14.01% |
2022 | $1.00 B | -43.42% |
2021 | $1.77 B | 23.64% |
2020 | $1.43 B | 59.15% |
2019 | $0.90 B | -8.92% |
2018 | $0.99 B | -0.85% |
2017 | $0.99 B | -18.25% |
2016 | $1.22 B | 148.44% |
2015 | $0.49 B | 439.63% |
2014 | $91.12 M | -5.6% |
2013 | $96.53 M | 105.19% |
2012 | $47.04 M | 68.14% |
2011 | $27.97 M | -19.97% |
2010 | $34.95 M | 165.91% |
2009 | $13.14 M | 39.27% |
2008 | $9.44 M | |
2001 | $1.33 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $89.65 B | 11,112.94% | ๐บ๐ธ USA |
Abbott Laboratories ABT | $40.32 B | 4,943.25% | ๐บ๐ธ USA |
Regeneron Pharmaceuticals REGN | $13.10 B | 1,538.33% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $45.53 B | 5,594.58% | ๐บ๐ธ USA |
LabCorp LH | $12.30 B | 1,438.31% | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | $2.00 B | 150.54% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | $16.00 B | 1,901.37% | ๐ฎ๐ฑ Israel |
Ardelyx ARDX | $0.15 B | -80.10% | ๐บ๐ธ USA |